Trends in incidence, therapy and outcome of localized nodal and extranodal marginal zone lymphomas: Declining incidence and inferior outcome for gastrointestinal sites

Leukemia and Lymphoma

Volumn 54, Issue 9, 2013, Pages 1891-1897

  Kuper Hommel, Marion J J ^a   Van De Schans, Saskia A M ^b   Vreugdenhil, Gerard ^c   Van Krieken, J Han J M ^d   Coebergh, Jan Willem W ^e,f  

^a Waikato DHB ^*  (New Zealand)

^b Netherlands Comprehensive Cancer Organisation The Netherlands   (Netherlands)

^c MÁXIMA MEDICAL CENTER   (Netherlands)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e Eindhoven Cancer Registry   (Netherlands)

^f ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Extranodal; Gastric lymphoma; Incidence; Marginal zone lymphoma; Nodal; Population based; Splenic

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER REGISTRY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DRUG TARGETING; FEMALE; HUMAN; HUMAN TISSUE; ICD-O-2; IRRADIATION; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MARGINAL ZONE LYMPHOMA; NETHERLANDS; OVERALL SURVIVAL; PRIORITY JOURNAL; TREATMENT OUTCOME; TREND STUDY;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; GASTROINTESTINAL NEOPLASMS; HUMANS; INCIDENCE; LYMPHOMA, B-CELL, MARGINAL ZONE; MALE; MIDDLE AGED; NEOPLASM STAGING; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84882946839     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.764421     Document Type: Article

References (34)

1. C. Clinical presentation and management of marginal zone lymphomas. Hematology Am Soc Hematol Educ Program 2005;307-313.
2. Luminari S, Cesaretti M, Rashid I, et al. Incidence, clinical characteristics and survival of malignant lymphomas :A populationbased study from a cancer registry in northern Italy. Hematol Oncol 2007;25:189-197.
3. Luminari S, Cesaretti M, Marcheselli L, et al. Decreasing incidence of gastric MALT lymphomas in the era of anti-Helicobacter pylori interventions: Results from a population-based study on extranodal marginal zone lymphomas. Ann Oncol 2010;21:855-859.
4. Campo E, Swerdlow SH, Harris NL et al. The 2008 WHO classification of lymphoid neoplasms and beyond: Evolving concepts and practical applications. Blood 2011;117:5019-5032.
5. Mazloom A, Medeiros LJ, McLaughlin PW, et al. Marginal zone lymphomas: Factors that aff ect the final outcome. Cancer 2010;116:4291-4298.
6. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms :A proposal from the International Lymphoma Study Group. Blood 1994;84:1361-13692.
7. Nathwani BN, Anderson JR, Armitage JO, et al. Marginal zone B-cell lymphoma :A clinical comparison of nodal and mucosa-associated lymphoid tissue types. Non-Hodgkin ' s Lymphoma Classification Project. J Clin Oncol 1999;17:2486-2492.
8. Kuper-Hommel MJ, van Krieken JH. Molecular pathogenesis and histologic and clinical features of extranodal marginal zone lymphomas of mucosa-associated lymphoid tissue type. Leuk Lymphoma 2012;53:1032-1045.
9. Isaacson P G. Update on MALT lymphomas. Best Pract Res Clin Haematol 2005;18:57-68.
10. Wotherspoon A C, Ortiz-Hidalgo C, Falzon M R, et al. Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma. Lancet 1991;338:1175-1176.
11. Zucca E, Bertoni F, Roggero E, et al. Molecular analysis of the progression from Helicobacter pylori-associated chronic gastritis to mucosa-associated lymphoid-tissue lymphoma of the stomach. N Engl J Med 1998;338:804-810.
12. Capelle LG, de Vries AC, Looman CW, et al. Gastric MALT lymphoma: Epidemiology and high adenocarcinoma risk in a nationwide study. Eur J Cancer 2008;44:2470-2476.
13. Wotherspoon AC, Doglioni C, Diss TC, et al. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet 1993;342:575-577.
14. Wotherspoon AC, Doglioni C, De Boni M, et al. Antibiotic treatment for low-grade gastric MALT lymphoma. Lancet 1994;343:1503.
15. Roggero E, Zucca E, Pinotti G, et al. Eradication of Helicobacter pylori infection in primary low-grade gastric lymphoma of mucosaassociated lymphoid tissue. Ann Intern Med 1995;122:767-769.
16. Bayerdorffer E, Neubauer A, Rudolph B, et al. Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobacter pylori infection. MALT Lymphoma Study Group. Lancet 1995;345:1591-1594.
17. Available from: Www.iknl.nl
18. Available from: Www.palga.nl
19. Percy C L, Holten V V, Muir C S. International classification of diseases for oncology. Geneva:World Health Organization;1990.
20. Fritz AG. International classification of diseases for oncology ICD-O3. Geneva:World Health Organization;2000.
21. van de Schans SA, Issa DE, Visser O, et al. Diverging trends in incidence and mortality, and improved survival of non-Hodgkin ' s lymphoma, in the Netherlands, 1989-2007. Ann Oncol 2011;23:171-182.
22. Morton LM, Wang SS, Devesa SS, et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 2006;107:265-276.
23. Allemani C, Tereanu C, et al. Incidence of hematologic malignancies in Europe by morphologic subtype: Results of the HAEMACARE project. Blood 2010;116:3724-3734.
24. Wotherspoon AC. Gastric MALT lymphoma and Helicobacter pylori. Yale J Biol Med 1996;69:61-68.
25. Parsonnet J, Hansen S, Rodriguez L, et al. Helicobacter pylori infection and gastric lymphoma. N Engl J Med 1994;330:1267-1271.
26. Roosendaal R, Kuipers EJ, Buitenwerf J, et al. Helicobacter pylori and the birth cohort eff ect: Evidence of a continuous decrease of infection rates in childhood. Am J Gastroenterol 1997;92:1480-1482.
27. Loffeld RJ, van der Putten AB. Changes in prevalence of Helicobacter pylori infection in two groups of patients undergoing endoscopy and living in the same region in the Netherlands. Scand J Gastroenterol 2003;38:938-941.
28. Liu H, Ye H, Ruskone-Fourmestraux A, et al. t(11;18) is a marker for all stage gastric MALT lymphomas that will not respond to H. pylori eradication. Gastroenterology 2002;122:1286-1294.
29. Liu H, Ruskon-Fourmestraux A, Lavergne-Slove A, et al. Resistance of t(11;18) positive gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradication therapy. Lancet 2001;357:39-40.
30. Available from: Www.hovon.nl/werkgroepen/studiewerkgroepen/lymfomen/ richtlijnen-lymfomen/dlbcl.html
31. Available from: Www.nccn.org/professionals/physician-gls/pdf/nhl.pdf
32. Janssen-Heijnen ML, van Spronsen DJ, Lemmens VE, et al. A population-based study of severity of comorbidity among patients with non-Hodgkin ' s lymphoma: Prognostic impact independent of International Prognostic Index. Br J Haematol 2005;129:597-606.
33. van Spronsen DJ, Janssen-Heijnen ML, Lemmens VE, et al. Independent prognostic eff ect of co-morbidity in lymphoma patients: Results of the population-based Eindhoven Cancer Registry. Eur J Cancer 2005;41:1051-1057.
34. Thieblemont C, Bastion Y, Berger F, et al. Mucosa-associated lymphoid tissue gastrointestinal and nongastrointestinal lymphoma behavior:Analysis of 108 patients. J Clin Oncol 1997;15:1624-1630.